Literature DB >> 12210708

Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC).

Paolo Perseghin1, Maria Dassi, Adriana Balduzzi, Attilio Rovelli, Sonia Bonanomi, Cornelio Uderzo.   

Abstract

A constant improvement in the performance of blood cell separators has been observed in recent years, allowing better yields in peripheral blood stem cell collection (PBSC) either from healthy donors or for autologous purposes. Nevertheless, to our knowledge, no reports on the efficiency of mononuclear cell (MNC) collection in patients undergoing extra-corporeal photochemotherapy (ECP) for graft-vs.-host-disease (GvHD) have been published. We retrospectively investigated the efficiency of 167 MNC collections performed consecutively in 12 patients between January 1999 and June 2001 by means of the COBE Spectra version 4.7 (V 4.7) or version 6.0 (V 6.0), for 109 and 58 procedures, respectively. MNC fractional extraction (FE) was higher in the V 6.0 group compared to the V 4.7 group : 0.59 +/- 0.21 vs. 0.51 +/- 0.22 (P < 0.05). However, platelet contamination was lower in the products obtained with V.6.0 compared to those obtained with V.4.7: 740 ( 630 x 10(3)/(L vs. 2,073 ( 1,429 x 10(3)/(L (P < 0.05). Only two patients with acute GvHD, both from V 4.7 group, required post-ECP platelet transfusion. The recently released version 6.0 allowed a satisfactory MNC yield with minimal platelet contamination in patients scheduled to undergo ECP for acute or chronic GvHD. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210708     DOI: 10.1002/jca.10021

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  7 in total

1.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

2.  Advances in haematological pharmacotherapy in 21st century.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-28       Impact factor: 0.900

3.  Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases.

Authors:  Paolo Perseghin
Journal:  Transfus Med Hemother       Date:  2007-12-21       Impact factor: 3.747

4.  Clinical Results of Extracorporeal Photopheresis.

Authors:  Nina Worel; Gerda Leitner
Journal:  Transfus Med Hemother       Date:  2012-07-26       Impact factor: 3.747

Review 5.  Extracorporeal Photopheresis in Graft-versus-Host Disease.

Authors:  Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro
Journal:  Transfus Med Hemother       Date:  2020-05-19       Impact factor: 3.747

6.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

7.  European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-06       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.